相关参考文献
注意：仅列出部分参考文献，下载原文获取全部文献信息。Docetaxel versus docetaxel alternating with gemcitabine as treatments of advanced breast cancer: final analysis of a randomised trial
H. Joensuu et al.
ANNALS OF ONCOLOGY (2010)
FEC versus sequential docetaxel followed by epirubicin/cyclophosphamide as adjuvant chemotherapy in women with axillary node-positive early breast cancer: a randomized study of the Hellenic Oncology Research Group (HORG)
Aristides Polyzos et al.
BREAST CANCER RESEARCH AND TREATMENT (2010)
Adjuvant Docetaxel for High-Risk, Node-Negative Breast Cancer.
Miguel Martin et al.
NEW ENGLAND JOURNAL OF MEDICINE (2010)
Breast Cancer Subtypes and Response to Docetaxel in Node-Positive Breast Cancer: Use of an Immunohistochemical Definition in the BCIRG 001 Trial
Judith Hugh et al.
JOURNAL OF CLINICAL ONCOLOGY (2009)
Docetaxel With Cyclophosphamide Is Associated With an Overall Survival Benefit Compared With Doxorubicin and Cyclophosphamide: 7-Year Follow-Up of US Oncology Research Trial 9735
Stephen Jones et al.
JOURNAL OF CLINICAL ONCOLOGY (2009)
Sequential docetaxel as adjuvant chemotherapy for early breast cancer (TACT): an open-label, phase III, randomised controlled trial
Paul Ellis et al.
LANCET (2009)
Estrogen receptor expression and efficacy of docetaxel-containing adjuvant chemotherapy in patients with node-positive breast cancer: Results from a pooled analysis
Fabrice Andre et al.
JOURNAL OF CLINICAL ONCOLOGY (2008)
Taxanes alone or in combination with anthracyclines as first-line therapy of patients with metastatic breast cancer
Martine J. Piccart-Gebhart et al.
JOURNAL OF CLINICAL ONCOLOGY (2008)
Taxane-based combinations as adjuvant chemotherapy of early breast cancer: A meta-analysis of randomized trials
Michele De Laurentiis et al.
JOURNAL OF CLINICAL ONCOLOGY (2008)
Concurrent doxorubicin plus docetaxel is not more effective than concurrent doxorubicin plus cyclophosphamide in operable breast cancer with 0 to 3 positive axillary nodes: North American breast cancer intergroup trial E 2197
Lori J. Goldstein et al.
JOURNAL OF CLINICAL ONCOLOGY (2008)
Adjuvant chemotherapy with sequential or concurrent anthracycline and docetaxel:: Breast International Group 02-98 randomized trial
Prudence Francis et al.
JNCI-JOURNAL OF THE NATIONAL CANCER INSTITUTE (2008)
Sequential adjuvant epirubicin-based and docetaxel chemotherapy for node-positive breast cancer patients:: The FNCLCC PACS 01 trial
Henri Roche et al.
JOURNAL OF CLINICAL ONCOLOGY (2006)
Phase III trial comparing doxorubicin plus cyclophosphamide with docetaxel plus cyclophosphamide as adjuvant therapy for operable breast cancer
Stephen E. Jones et al.
JOURNAL OF CLINICAL ONCOLOGY (2006)
Toxicity and health-related quality of life in breast cancer patients receiving adjuvant docetaxel, doxorubicin, cyclophosphamide (TAC) or 5-fluorouracil, doxorubicin and cyclophosphamide (FAC):: impact of adding primary prophylactic granulocyte-colony stimulating factor to the TAC regimen
M. Martin et al.
ANNALS OF ONCOLOGY (2006)
Benefit of taxanes as adjuvant chemotherapy for early breast cancer - Pooled analysis of 15,500 patients
Emilio Bria et al.
CANCER (2006)
Meta-analysis when only the median survival times are known: A comparison with individual patient data results
S Michiels et al.
INTERNATIONAL JOURNAL OF TECHNOLOGY ASSESSMENT IN HEALTH CARE (2005)
Effects of radiotherapy and of differences in the extent of surgery for early breast cancer on local recurrence and 15-year survival:: an overview of the randomised trials
O Abe et al.
LANCET (2005)
A systematic review of taxane-containing regimens for metastatic breast cancer
D Ghersi et al.
BRITISH JOURNAL OF CANCER (2005)
Adjuvant docetaxel for node-positive breast cancer
M Martin et al.
NEW ENGLAND JOURNAL OF MEDICINE (2005)
Life-threatening sepsis associated with adjuvant doxorubicin plus docetaxel for intermediate-risk breast cancer
EGC Brain et al.
JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION (2005)
Effects of chemotherapy and hormonal therapy for early breast cancer on recurrence and 15-year survival:: an overview of the randomised trials
O Abe et al.
LANCET (2005)
Docetaxel and paclitaxel in the treatment of breast cancer: A review of clinical experience
J Crown et al.
ONCOLOGIST (2004)
Improved outcomes from adding sequential paclitaxel but not from escalating doxorubicin dose in an adjuvant chemotherapy regimen for patients with node-positive primary breast cancer
IC Henderson et al.
JOURNAL OF CLINICAL ONCOLOGY (2003)
Publication and related bias in meta-analysis: Power of statistical tests and prevalence in the literature
JAC Sterne et al.
JOURNAL OF CLINICAL EPIDEMIOLOGY (2000)
The role of meta-analyses in assessing cancer treatments
R Sylvester et al.
EUROPEAN JOURNAL OF CANCER (2000)
分享论文
